Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Code

Type your Poster Code, then hit apply

Showing 1,267 results.

Thumbnail for Survival and Cardiovascular Outcomes Associated With GLP-1 Receptor Agonist Exposure in Patients With Multiple Myeloma and Metabolic Comorbidities: A Propensity-Matched TriNetX Analysis

MM - 857

Survival and Cardiovascular Outcomes Associated With GLP-1 Receptor Agonist Exposure in Patients With Multiple Myeloma and Metabolic Comorbidities: A Propensity-Matched TriNetX Analysis

Nnamdi Omenuko

Poster Presenter: Nnamdi Omenuko

Thumbnail for Comparative Toxicity of Menin Inhibitor-Based Combination therapy in newly diagnosed Acute Myeloid Leukemia: Venetoclax-containing Versus Non-Venetoclax regimens

AML - 858

Comparative Toxicity of Menin Inhibitor-Based Combination therapy in newly diagnosed Acute Myeloid Leukemia: Venetoclax-containing Versus Non-Venetoclax regimens

Vaishnavi Rao

Poster Presenter: Vaishnavi Rao

Previous 1...67 68 69 70 71 72 73...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Mortality and Bleeding Tradeoffs Associated With Oral Anticoagulation in BTK Inhibitor-Treated Chronic Lymphocytic Leukemia Patients With Atrial Fibrillation/Flutter: A Propensity-Matched TriNetX Analysis

CLL - 860

Mortality and Bleeding Tradeoffs Associated With Oral Anticoagulation in BTK Inhibitor-Treated Chronic Lymphocytic Leukemia Patients With Atrial Fibrillation/Flutter: A Propensity-Matched TriNetX Analysis

Alexander Mays

Poster Presenter: Alexander Mays

Thumbnail for Urinary Mast Cell Metabolites Versus Serum Tryptase for Monitoring Clinical Response to Cytoreductive Therapy in Indolent Systemic Mastocytosis

MPN - 861

Urinary Mast Cell Metabolites Versus Serum Tryptase for Monitoring Clinical Response to Cytoreductive Therapy in Indolent Systemic Mastocytosis

Cecilia Arana-Yi

Poster Presenter: Cecilia Arana-Yi

Thumbnail for Infections in Chronic Lymphocytic Leukemia: A National Inpatient Sample Analysis of Prevalence and Mortality

CLL - 864

Infections in Chronic Lymphocytic Leukemia: A National Inpatient Sample Analysis of Prevalence and Mortality

Rabia Iqbal

Poster Presenter: Rabia Iqbal

Thumbnail for Post-CAR-T Relapse in DLBCL: Real-World Salvage Therapy Patterns and Outcomes at a Tertiary Academic Center

ABCL - 865

Post-CAR-T Relapse in DLBCL: Real-World Salvage Therapy Patterns and Outcomes at a Tertiary Academic Center

Jivtesh Singh

Poster Presenter: Jivtesh Singh

$Thumbnail for Three-Year Follow-Up of Dose-Dense Mini-CVD in Combination with Inotuzumab Ozogamicin and Blinatumomab for Patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia$

ALL - 866

Three-Year Follow-Up of Dose-Dense Mini-CVD in Combination with Inotuzumab Ozogamicin and Blinatumomab for Patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Hannah Goulart

Poster Presenter: Hannah Goulart

Thumbnail for Postmarketing Safety Signals of Revumenib (Menin-KMT2A Inhibitor) vs Acute Myeloid Leukemia-Targeted Therapies: A Class-Restricted Disproportionality Analysis of the FDA Adverse Event Monitoring System (2016-2026)

AML - 867

Postmarketing Safety Signals of Revumenib (Menin-KMT2A Inhibitor) vs Acute Myeloid Leukemia-Targeted Therapies: A Class-Restricted Disproportionality Analysis of the FDA Adverse Event Monitoring System (2016-2026)

Arashdeep Singh

Poster Presenter: Arashdeep Singh

Thumbnail for Clinical Outcomes Among Anticoagulated Patients with CLL and Atrial Fibrillation/Flutter Treated with First- Versus Second-Generation BTK Inhibitors

CLL - 868

Clinical Outcomes Among Anticoagulated Patients with CLL and Atrial Fibrillation/Flutter Treated with First- Versus Second-Generation BTK Inhibitors

Nnamdi Omenuko

Poster Presenter: Nnamdi Omenuko

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors